FDA Catching Antibiotic Incentive Bug: Agency Primed To Consider Ways To Shorten Route for Resistant-Strain Drugs
• By Laura Helbling
FDA is working along a parallel path to other several other government agencies to find ways to stimulate drug development for anti-infectives active against resistant strains. Top policy leaders in the drug review divisions reflect the new interest by thinking aloud how historical controls or oncology-like accelerated approvals might speed the process.
By Laura Helbling
Antibiotic resistance is increasing, and one answer may be for the Food & Drug Administration to reduce regulatory resistance facing...
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Pink Sheet for daily insights
